Accuray’s CyberKnife System shows disease control, safety in NEJM study

Accuray announced that results of the PACE-B – Prostate Advances in Comparative Evidence – trial were published in the New England Journal of Medicine. The research builds on previously reported data and shows that at five years, stereotactic body radiation therapy – SBRT – provides comparable rates of cancer control, tolerability and sexual functioning to conventional radiotherapy, while reducing the overall treatment timeframe from up to 39 days of treatment to just five days. The Accuray CyberKnife System was used in the SBRT treated arm of the PACE-B study and showed excellent disease control with low rates of toxicity for men with prostate cancer. Both groups attained high rates of cancer control at five years, with similar rates of 94.6% for CRT and 95.8% for SBRT achieved without the use of androgen deprivation therapy. SBRT was well-tolerated and treatment-related impairment and bother were comparable to CRT. 41% of men treated with SBRT in the study received treatment using the CyberKnife platform.